ArticleAfrican health sciences2024
Network-based pharmacology to predict the mechanism of qianghuo erhuang decoction in the treatment of rheumatoid arthritis.
Article in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Revealing the Pharmacological Mechanism of Tibetan Medicine Wugeng San in Treating Rheumatoid Arthritis Through an Integrated Strategy of Chemical Composition Analysis, Network Pharmacology, Machine Learning, and In Vivo Experiments.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Editor's choice: Infections, sexual reproductive health and non-communicable diseases.African health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the mechanisms of Qianghuo Erhuang Decoction (QED) in the treatment of rheumatoid arthritis (RA), we performed compounds, targets prediction and network analysis using a network pharmacology method. Methodology: We collected active ingredients and targets of QED according to the database of Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) and selected therapeutic targets on RA. "drug-ingredient-target" network was made for the intersecting genes. The STRING database was used for constructing a protein-protein interaction network (PPI) for the intersection genes, and R version 4.1.2 software was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Results: We found that there were 141 main active ingredients in QED, of which the main core active ingredients were: β-sitosterol, stigmasterol, baicalein, wogonin, kaempferol, etc., involving 166 RA genes. GO enrichment analysis results showed that QED involved 2229 biological processes, 78 cell components and 212 molecular functions. QED might interfere and treat RA through lipid and atherosclerosis, cancer pathways, PI3K-Akt, AGE-RAGE, IL-17, TNF, as well as HIF-1 signaling pathways. Conclusions: QED may treat RA by regulating inflammation-related signaling pathways, angiogenesis signaling pathways, and reducing the expression of inflammatory factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.